Multiple myeloma mimicking metastatic lung cancer

Metastatik akciğer kanserini taklit eden multipl miyelom

Yavuz FURUNCUOĞLU,¹ Yalçın ÇIRAK,² Hacı Mehmet TÜRKK,³ Melih BAŞAR,⁴ Hülya ORTAPAMUK,⁵ Ahmet Cemil KAUR⁶

¹Department of Internal Medicine, Bahçeşehir University Faculty of Medicine, İstanbul
²Department of Oncology, Bahçeşehir University Faculty of Medicine, İstanbul
³Department of Oncology, Bezmi Alem University Faculty of Medicine, İstanbul
⁴Department of Internal Medicine, Göztepe Medical Park Hospital, İstanbul
⁵Department of Nuclear Medicine, Bahçeşehir University Faculty of Medicine, İstanbul
⁶Private Pathology Laboratory, İstanbul

Multiple myeloma is a hematological malignancy characterized by a clonal proliferation of plasma cells in the bone marrow. Extramedullary dissemination of multiple myeloma is uncommon. Only in rare cases, the malignant plasma cells of multiple myeloma had infiltrated the lung parenchyma. In this case report, we presented a case of multiple myeloma with lung plasmacytoma, in a 42-year-old patient, hospitalized for pain and infiltrative mass in the right lung. The results of his initial evaluation with computed tomography and positron emission tomography scanning, resembled lung tumor with bone metastasis. Surprisingly, biopsies from lung tumor and bone metastasis, revealed malignant plasma cells. We found M spike in protein electrophoresis and lambda monoclonal band in immune electrophoresis. A bone marrow biopsy evaluation was done and justified multiple myeloma diagnosis before hematology referral. Multiple myeloma diagnosis at the age of 42 is quite rare.

Keywords: Cancer; lung; metastasis; myeloma.

Multiple myeloma (MM) is a hematological malignancy characterized by a clonal proliferation of plasma cells in the bone marrow. It is a common disease, which is accounting for about 10% of all hematologic malignancies in the United States.

Extramedullary dissemination of multiple myeloma is uncommon. Only in rare cases, the malignant plasma cells of multiple myeloma had infiltrated the lung parenchyma.

A 42-year-old male patient presented in our outpatient clinic with the complaint of right sided chest pain. There were no weight loss, fever, sweating or cough. He smoked cigarettes 70 packs/year.
On his physical examination; his blood pressure was 130/80 mmHg, heart and lung sounds were normal. There were no prominent lymph node enlargements. Also there were no significant pathological findings in abdominal examination. There was no visible mass in his chest wall. His medical history was also insignificant. Results of his routine blood tests were as follows:

Hb, 14.2 g/dL; platelet count, 228x109/L; and white blood cell (WBC), 13.6x109/L (segmented neutrophil, 51.3%; lymphocyte, 35.8%; monocyte, 8.9%; and eosinophil, 3.09%); ESR: 83 mm/h CRP: 149 mg/L (normal range <8.2); Creatinine, 0.95 mg/dL (reference range, 0.6–1.2 g/dL); Lactate dehydrogenase, 254 U/L (reference range, 125–243 U/L). AST-ALT, ALP were normal.

Computed tomography (CT) (GE Hangwei medical system Co. Beijing P.R.China) examination of the chest revealed a right lung mass with sternal and vertebral metastases (Fig. 1).

This mass was a lobulated tumour, located at the anteriobasalis of the right lung upper lobe with a dimension of 97x65 mm in diameter. It had been extended anteriorly to pectoralis muscle margin, destructing 3rd and 4th ribs. It had manubrium sterni metastasis of 4x4.5 cm in diameter and a lytic mass in T11 vertebrae.

A consecutive Positron emission tomography imaging with flurodeoxyglucose (FDG PET/CT) (Siemens biograph 2 LSO Germany) was performed. It also showed a malignant hypermetabolic mass of 95x60 in diameter (SUV max: 12.7), located at the anteriobasalis of the right lung upper lobe which had been extended anteriorly to pectoralis muscle margin, destructing 3rd and 4th ribs. It also revealed hypermetabolic destructive bone lesions at manubrium sterni (SUV max: 8.0), right humerus shaft (SUV max: 15.0), T11 (SUV max: 5.9) and L4 vertebrae (SUV max: 6.4). There were partly hypermetabolic, mostly sclerotic and ametabolic widespread skeletal areas of malignant lesions. There were bilateral pleural effusions mainly considered as malignant and mediastinal reactive lymph nodes. Also there were hypermetabolic lymph nodes at L4 vertebrae level which were considered as metastasis (Fig. 2).

CT guided multiple biopsies were taken from the lung mass and the metastatic lesion of vertebrae.

Tru-cut biopsy of right lung mass, Malignant tumour with plasma cells (Plasma cell myeloma) (Fig. 3a) and biopsy from L4 vertebrae showed
degenerated bone trabecula with atypical plasma cells (Fig. 3b).

Right after the surprising results of the pathological evaluation, protein and immune electrophoresis were done. Their results were as follows;

Total protein: 5.3 (reference range, 6.4–8.3 g/dL); Albumin, 2.52 g/dL (reference range, 3.5–5.2 g/dL); Alfa 1: 4.65% (2.2–4.6) Alfa 2: 22.79% (8.2–12.5) Beta 1: 9.8% (7.2–14.2) Gamma: 15.2% (11.5–18.6) M spike: 2.94 g IgA: 11.2 (40–350), IgG: 390 (650–1600), IgM: 11 (50–300), kappa light chain: 66 (170–370) and lambda was measured at 424 mg/dl (reference range, 90–210 mg/dl).

In the gel electrophoresis revealed a monoclonal band in lambda antisera and lambda FLC was measured at 424 mg/dl (reference range, 90–210 mg/dl).

Results were consistent with multiple myeloma, so a bone marrow biopsy was performed.

The result of bone marrow biopsy showed CD38, CD56 and lambda positive, kappa negative plasma cells infiltrating 90% of bone marrow space. Conclusion was plasma cell myeloma showing monoclonal of lambda light chain (Fig. 3c).

Based on these results, the patient was diagnosed as multiple myeloma with extramedullary dissemination, primarily into the lung.

The patient was referred to the hematology department for chemotherapy. After treatment bone marrow biopsy revealed total cure. Patient’s follow up is still going on in hematology outpatient clinic.

Multiple myeloma is rare in young population. Plasmacytoma resembling metastatic lung cancer in the young is very rare. In that manner, we decided to present this case.

**DISCUSSION**

Plasma cell myeloma (PCM) is a malignant hematologic disease characterized by the proliferation of neoplastic plasma cells, producing excessive amounts of monoclonal immunoglobulin (Ig)
or light chain.\[1,2\]

Although plasma cells are widely distributed throughout the body, PCM is found most often within the bone and bone marrow (BM), while the dissemination of extramedullary plasmacytoma into the lung has been reported to be very rare.\[3\]

MM establishes 27% of all biopsied bone tumors, and 1% of all malignancies.\[4,5\] It is seen typically between ages 50 to 70 and it is rare before the age of 40.\[4\] It is seen twice as much in men than in women.

Classically, PCM occurs mainly in BM-rich bone.\[6\] Therefore, primary clinical presentation includes bone pain, and anemia.\[7,8\]

Extramedullary plasmacytomas have been reported in 15–20% of patients at diagnosis and in an additional 15% during the course of PCM, and these patients are often associated with high-risk diseases like myelomatous pleural effusion (MPE).\[9\]

Extramedullary existence of plasmacytoma is not common and the incidence of thoracic cases is low, especially in patients presenting with pulmonary plasmacytoma and malign pleural effusion to simulate a pleural mesothelioma or lung cancer.\[6,10\]

We report here a unique presentation of PCM to include monoclonal components and lung plasmacytoma as initially mistaken for metastatic lung cancer.

In this case, a precise diagnosis of PCM is difficult when only clinical and imaging studies are conducted. In order to discriminate extramedullary PCM from other malignancies, biochemical assays such as electrophoresis are very helpful to confirm the presence of monoclonal components when performed along with pathologic examinations of the mass and bone marrow.

REFERENCES